Epithalon (Epitalon)

Peptidesubcutaneous · inferred

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the pineal gland peptide epithalamin. Activates telomerase in human somatic cells, elongating telomeres. Studied for anti-aging effects. Half-life estimated at <1 hour due to its small tetrapeptide structure. Typically administered as 5-10 mg SC daily for 10-20 day cycles.

Projected serum levels — 5 mg, once daily

Epithalon (Epitalon)
Epithalon (Epitalon) modeled serum levels, 5 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 5 mg once daily (subcutaneous).

Modeled steady state after ~1 days: peak ≈ 2.0 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 5 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
29 min
Common dose
5 mg
Suggested maximum
10 mg/day
Reference dose range
2.5–10 mg (single dose)
Suggested cadence
once daily

Research behind this entry

  1. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells Khavinson VK et al. · Bulletin of Experimental Biology and Medicine, 2003 DOI

    Demonstrated that Epithalon induced telomerase expression, enzymatic activity, and telomere elongation in human fetal fibroblast cultures that were previously telomerase-negative.

  2. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties Khavinson VK et al. · Pharmaceuticals, 2025 DOI

    Comprehensive review of Epitalon covering telomerase activation, melatonin regulation, antioxidant effects, and evidence from over two decades of research into anti-aging applications.

2 published studies referenced in the app, each with a plain-language summary.